Market Cap (In USD)
5.89 Million
Revenue (In USD)
4.91 Million
Net Income (In USD)
-13.31 Million
Avg. Volume
53.17 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.98-2.67
- PE
- -
- EPS
- -
- Beta Value
- 0.69
- ISIN
- US72941H5090
- CUSIP
- 72941H400
- CIK
- 1095981
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Marc H. Hedrick M.B.A., M.D.
- Employee Count
- -
- Website
- https://www.plustherapeutics.com
- Ipo Date
- 2001-07-11
- Details
- Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
More Stocks
-
C-PN
-
CG
-
NXLLFNuix Limited
NXLLF
-
PHRMASIPhaarmasia Limited
PHRMASI
-
PCG-PA
-
YPSNYpsomed Holding AG
YPSN
-
DYNAVSNDynavision Limited
DYNAVSN
-
AM7